跳轉至內容
Merck
全部照片(1)

重要文件

P2120000

Piretanide

European Pharmacopoeia (EP) Reference Standard

同義詞:

4-Phenoxy-3-(1-pyrrolidinyl)-5-sulfamoylbenzoic acid

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C17H18N2O5S
CAS號碼:
分子量::
362.40
分類程式碼代碼:
41116107
NACRES:
NA.24
暫時無法取得訂價和供貨情況

等級

pharmaceutical primary standard

API 家族

piretanide

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

[S](=O)(=O)(N)c1c(c(cc(c1)C(=O)O)N3CCCC3)Oc2ccccc2

InChI

1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)

InChI 密鑰

UJEWTUDSLQGTOA-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Piretanide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

N Takamura et al.
Pharmaceutical research, 13(7), 1015-1019 (1996-07-01)
The purpose of this study was to investigate the binding mechanism of loop diuretics with HSA and to characterize the binding site on HSA. Quantitative analysis of potential interaction between ligands bound to HSA was performed by equilibrium dialysis and
G Ruf et al.
European journal of clinical pharmacology, 46(6), 545-550 (1994-01-01)
The pharmacokinetics and pharmacodynamics of single oral doses of 5 mg ramipril and 6 mg piretanide administered separately and in combination were determined in a single blind, randomised, 3-period cross-over study in 24 healthy male volunteers. The peak plasma concentrations
V Homuth et al.
The American journal of cardiology, 72(9), 666-671 (1993-09-15)
To test the dose responses of piretanide, ramipril, and their combination in patients with essential hypertension, a prospective, randomized, double-blind, placebo-controlled trial was conducted in 480 patients. Twelve separate groups were studied: placebo, piretanide 3 mg, piretanide 6 mg, ramipril
Effect of Na/K/2Cl transporter inhibition with piretanide on postischemic kidney function.
D Abendroth et al.
Transplantation proceedings, 28(1), 83-84 (1996-02-01)
R A Brown et al.
Journal of vascular research, 36(6), 492-501 (2000-01-12)
The inhibition by loop diuretics of K efflux (tracer (86)Rb) from the rat femoral arterial smooth muscle was measured in normotension and in DOCA-salt hypertension. The sensitivity sequence (bumetanide > piretanide > furosemide) was the characteristic pharmacological profile of (Na+K+Cl)

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務